Last Updated : May 3, 2024
The latest CADTH Reimbursement Review reports are posted to this page. CADTH reimbursement reviews are comprehensive assessments of the clinical effectiveness and cost-effectiveness, as well as patient and clinician perspectives, of a drug or drug class. The assessments inform non-binding recommendations that help guide the reimbursement decisions of Canada's federal, provincial, and territorial governments, with the exception of Quebec. Implementation advice and funding algorithms are provided where applicable.
| Brand Name | Generic Name | Therapeutic Area | Recommendation Type | Project Status Sort descending | Date Submission Received | Date Recommendation Issued |
|---|---|---|---|---|---|---|
| Calquence | Acalabrutinib | Chronic Lymphocytic Leukemia (CLL) | Reimburse with clinical criteria and/or conditions | Complete | ||
| Odomzo | Sonidegib | Basal Cell Carcinoma | Do not reimburse | Complete | ||
| Venclexta | Venetoclax Obinutuzumab | Obinutuzumab for CLL | Reimburse with clinical criteria and/or conditions | Complete | ||
| Keytruda | Pembrolizumab | head and neck squamous cell carcinoma (HNSCC) | Reimburse with clinical criteria and/or conditions | Complete | ||
| Zepzelca | lurbinectedin | metastatic small cell lung cancer (SCLC) | Do not reimburse | Complete | ||
| Dayvigo | lemborexant | Insomnia | Do not reimburse | Complete | ||
| Keytruda | pembrolizumab | Renal cell carcinoma, adjuvant | Reimburse with clinical criteria and/or conditions | Complete | ||
| Gavreto | pralsetinib | RET fusion-positive non-small cell lung cancer | Reimburse with clinical criteria and/or conditions | Complete | ||
| Livtencity | maribavir | Post-transplant cytomegalovirus infection | Reimburse with clinical criteria and/or conditions | Complete | ||
| Radicava | edaravone | Amyotrophic lateral sclerosis | Reimburse with clinical criteria and/or conditions | Complete |
Last Updated : May 3, 2024